Physician profile
John Bernat
NPI 1215923115
$5,371.10
in general payments reported to CMS, 2019-2025
25 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $145 · 2021: $219 · 2022: $378 · 2023: $1,735 · 2024: $1,160 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,778 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,777.98 |
| Education | $266.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,544.30 | 2021-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,439.57 | 2019-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $451.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $330.97 | 2019-2025 | |
| Genzyme Corporation | $301.41 | 2023-2025 | |
| Dermavant Sciences, INC. | $270.17 | 2023-2024 | Vtama |
| Incyte Corporation | $174.75 | 2024-2025 | Opzelura |
| Leo Pharma INC. | $134.89 | 2023-2024 | Adbry |
| Lilly USA, LLC | $119.16 | 2023-2025 | Ebglyss, Taltz |
| Journey Medical Corporation | $97.33 | 2025 | |
| Sun Pharmaceutical Industries INC. | $74.05 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 | |
| Pfizer INC. | $61.76 | 2023-2025 | |
| Genentech USA, INC. | $57.89 | 2019-2021 | |
| Ucb, INC. | $44.05 | 2023-2025 | Bimzelx, Cimzia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $33.86 | 2024-2025 | Nemluvio |
| Allergan, INC. | $30.73 | 2019 | |
| Revance Therapeutics, INC. | $21.00 | 2025 | Daxxify |
| Amgen INC. | $19.33 | 2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $18.85 | 2024 | Sotyktu |
| Dermira, INC. | $17.59 | 2019 | |
| Kyowa Kirin, INC. | $16.60 | 2023 | Poteligeo |
| Regeneron Healthcare Solutions, INC. | $15.22 | 2023 | Dupixent |
| Smith+Nephew, INC. | $14.10 | 2019 | |
| Organon LLC | $10.21 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bernat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.